Acute Myeloid Leukemia

Acute Myeloid Leukemia

High HSPA8 Expression Predicts Adverse Outcomes of Acute Myeloid Leukemia

In this study, public datasets available from the TCGA and GEO are mined to discover the association between the expression of HSPA8 and clinical phenotypes of CN-AML.

BMC Cancer
Optimizing Transplant Approaches and Post-Transplant Strategies for Patients With Acute Myeloid Leukemia

The increasingly important role of allo-SCT in the management of AML has been underpinned by two important advances.

Frontiers in Oncology
Targeting the Metabolic Vulnerability of Acute Myeloid Leukemia Blasts With a Combination of Venetoclax and 8-Chloro-Adenosine

BCL‐2 inhibition through venetoclax targets acute myeloid leukemia blast cells and leukemic stem cells.

Journal of Hematology & Oncology

IL-37 Was Involved in Progress of Acute Myeloid Leukemia Through Regulating IL-6 Expression

The aim of this study is to evaluate IL-37 as a prognostic factor and its possible mechanism of action.

Cancer Management and Research
Targeting GLUT1 in Acute Myeloid Leukemia to Overcome Cytarabine Resistance

Study investigators present a detailed structural and functional analysis of compounds that inhibit glucose transporters and sensitize AML cells for chemotherapy.

More Strategies Needed to Eradicate Minimal Residual Disease in AML

More potent strategies are needed to induce minimal residual disease in acute myeloid leukemia patients before they proceed to transplant.

Oncology Times - Latest Articles
Arsenic Trioxide Synergistically Promotes the Antileukaemic Activity of Venetoclax by Downregulating Mcl-1 in Acute Myeloid Leukemia Cells

Study investigators assess the combined effect of venetoclax and arsenic trioxide on leukaemic cell viability, apoptosis, combination index, and cell cycle in the human LSC-like KG1 and KG1a cells.

Experimental Hematology & Oncology
Newly Diagnosed Acute Myeloid Leukemia in a Patient With Severe SARS-CoV-2 Infection

This case suggests that in all patients with a persistent and/or complicated infection, even during pandemics, the presence of an underlying hematologic malignancy should always be taken into consi

One Stone, Two Birds: The Roles of Tim-3 in Acute Myeloid Leukemia

Targeting Tim-3 kills two birds with one stone by balancing the immune system and eliminating leukemia stem cells in AML.

Frontiers in Immunology
Ivosidenib or Enasidenib Combined With Intensive Chemotherapy in Patients With Newly Diagnosed AML

Ivosidenib or enasidenib combined with induction and consolidation chemotherapy were both well tolerated in newly diagnosed mIDH1/2 AML.

Prospective KIR Genotype Evaluation of Hematopoietic Cell Donors is Feasible With Potential to Benefit Patients With AML

This study demonstrates that donor KIR typing is feasible, and prioritization of donors with certain KIR3DL1 genotypes may confer a protection from relapse after HCT in patients with AML.

Blood Advances
The Interactome Between Metabolism and Gene Mutations in Myeloid Malignancies

The study of metabolic deregulation in myeloid malignancies has led to the investigation of metabolic-targeted therapies considering that cells undergoing leukemic transformation...

International Journal of Molecular Sciences
Immunosuppressive Cell Subsets and Factors in Myeloid Leukemias

This review describes the factors and cells that constitute immunosuppressive microenvironment of myeloid leukemias. 

Inhibition of EZH2 by Chidamide Exerts Antileukemia Activity and Increases Chemosensitivity Through Smo/Gli-1 Pathway in Acute Myeloid Leukemia

Aberrant activation of HDACs results in uncontrolled proliferation and blockade of differentiation, and HDAC inhibition has been investigated as epigenetic therapeutic strategy against AML.

Journal of Translational Medicine
Redirecting the Immune Microenvironment in Acute Myeloid Leukemia

This review examines innovative immunotherapeutic strategies and their mechanisms of action in pediatric AML.

Functional Genetic Variants in ATG10 Are Associated with Acute Myeloid Leukemia

To date, diagnostic tools to monitor individuals at higher risk of developing AML are scarce.

Chromatin-Spliceosome Mutations in Acute Myeloid Leukemia

The aim of this review is to discuss the genetic and clinical characteristics of CS-AML and roles of driver mutations defining this unique genomic subgroup of AML.

The Characteristics of circRNA as Competing Endogenous RNA in Pathogenesis of Acute Myeloid Leukemia

As one of the novel molecules, circRNA has been identified closely involved in the pathogenesis of many diseases.

BMC Cancer
Use of Measurable Residual Disease to Evolve Transplant Policy in Acute Myeloid Leukemia: A 20-Year Monocentric Observation

Upfront genetics/cytogenetics and minimal measurable disease are becoming relevant biomarkers in the process of post-remission transplant allocation in AML.

High-Throughput Drug Screening Reveals Pyrvinium Pamoate as Effective Candidate Against Pediatric MLL-Rearranged Acute Myeloid Leukemia

Study investigators identify pyrvinium pamoate as a novel candidate drug effective against MLL-rearranged AML.

Translational Oncology
Pathogenic Roles of S100A8 and S100A9 Proteins in Acute Myeloid and Lymphoid Leukemia

The therapeutic targeting of S100A8 and S100A9 appears to be a promising way to improve treatment efficiency in acute leukemias.

Expression of a Recombinant FLT3 Ligand and its Emtansine Conjugate as a Therapeutic Candidate Against Acute Myeloid Leukemia Cells With FLT3 Expression

Here, E. coli is used as a host to express recombinant human FLT3 ligand, which is used as a specific vehicle to deliver cytotoxic drugs to FLT3 + AML cells.

Deregulated Expression of Circular RNAs in Acute Myeloid Leukemia

Study investigators hypothesize that circRNA expression is deregulated in acute myeloid leukemia and that circRNA candidates might contribute to the pathogenesis of the disease.

Blood Advances
Gene Expression Signature Predicts Relapse in Adult Patients With Cytogenetically Normal Acute Myeloid Leukemia

The weighted expressions of 7 coding and 3 noncoding genes is strongly associated with relapse in CN-AML patients.

Blood Advances
miR-621 May Suppress Cell Proliferation via Targeting lncRNA SNHG10 in Acute Myeloid Leukemia

This study explores the role of SNHG10 in AML.

Cancer Management and Research
Haploidentical Age-Adapted Myeloablative Transplant and Regulatory and Effector T Cells for Acute Myeloid Leukemia

The combination of myeloablative conditioning with regulatory and conventional T-cell immunotherapy eradicates AML.

Blood Advances
Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Combination of decitabine or guadecitabine with NY-ESO-1 vaccine enhances vaccine immunogenicity in AML patients. 

Frontiers in Oncology
Glasdegib in Combination With Low-Dose Cytarabine for the Outpatient Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Unfit Patients

Study investigators retrospectively collect clinical data on 31 R/R AML patients who were treated with outpatient glasdegib and low-dose Cytarabine (LDAraC) at their institution.

The Prognostic Value of the Peripheral Blood Cell Counts Changes During Induction Chemotherapy in Chinese Patients With Adult Acute Myeloid Leukemia

This study investigates the prognostic value of the circulating peripheral blood cell counts changes in AML at different time points during induction chemotherapy.

The Application of BH3 Mimetics in Myeloid Leukemias

The most significant example of these is the BCL-2-specific inhibitor venetoclax, given in combination with standard-of-care therapies with great success in AML in clinical trials.

Cell Death & Disease
Single-Cell Map of Diverse Immune Phenotypes in the Acute Myeloid Leukemia Microenvironment

Knowledge of immune cell phenotypes, function, and developmental trajectory in AML microenvironment is essential for understanding mechanisms of evading immune surveillance and...

Biomarker Research
Development of a Poor-Prognostic-Mutations Derived Immune Prognostic Model for Acute Myeloid Leukemia

Study investigators develop and validate an IPM derived from mutations related with poor prognosis in AML, which would provide new biomarkers for patient stratification and...

Scientific Reports
Effectiveness of Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia

This randomized clinical trial seeks to answer the question of the effect of IPC on patient-reported and end-of-life outcomes for patients with acute myeloid leukemia.

JAMA Oncology
Early Transplantation-Related Mortality After Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Leukemia

This is a nationwide population cohort study involving patients with acute leukemia who underwent allo-HCT between 2003 and 2015.

BMC Cancer
Allogeneic Stem Cell Transplantation in Acute Leukemia Patients After COVID-19 Infection

The risk for severe and fatal courses of COVID-19 is particularly high after allogeneic hematopoietic stem cell transplantation.

Measurable Residual Disease in Elderly Acute Myeloid Leukemia: Results From the PETHEMA-FLUGAZA Phase 3 Clinical Trial

Attaining undetectable MRD after semi-intensive therapy or hypomethylating agents is prognostically relevant in older patients with AML.

Blood Advances
CD123 Is Consistently Expressed on NPM1-Mutated AML Cells

A deep knowledge of the distribution of selected antigens on the surface of NPM1-mutated AML cells may help optimizing new therapies for this

New Maintenance Treatment for Acute Myeloid Leukemia Prolongs Lives

This is the first time a maintenance treatment for AML has shown such a strong benefit for patients, and it is already being adopted as part of standard care.

Oncology Times - Latest Articles
Genomic Characterization of Relapsed Acute Myeloid Leukemia Reveals Novel Putative Therapeutic Targets

Mutations in ARID1A and CSF1R are recurrently gained at relapse in AML and represent novel therapeutic options for patients with relapsed AML.

Blood Advances
Transformation From Acute Promyelocytic Leukemia to Acute Myeloid Leukemia With a CEBPA Double Mutation

The transformation of APL to acute mononuclear leukemia during treatment is a rare clinical phenomenon, and no CCAAT/enhancer-binding protein alpha double mutations have been reported.

Maintenance Therapy in AML

This review summarizes prior and ongoing maintenance therapy approaches in AML and highlights some of the most promising strategies.

Frontiers in Oncology
Multiplexed Single‐Cell Mass Cytometry Reveals Distinct Inhibitory Effects on Intracellular Phosphoproteins by Midostaurin in Combination With Chemotherapy in AML Cells

The multitargeted kinase inhibitor midostaurin (PKC412) in combination with standard chemotherapy (daunorubicin and cytarabine) was recently shown to increase overall survival of AML patients.

CDK6 is a Potential Prognostic Biomarker in Acute Myeloid Leukemia

This study reveals that CDK6 might be a potential diagnostic and prognostic biomarker in non-APL AML patients.

Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia

Flotetuzumab is associated with acceptable safety and evidence of activity in AML patients with PIF/ER.

Novel Prognostic Genes and Subclasses of Acute Myeloid Leukemia Revealed by Survival Analysis of Gene Expression Data

This study discusses prognostic biomarkers that could effectively classify AML patients and provide guidance for treatment decision making.

Development and Validation of a Novel Circular RNA as an Independent Prognostic Factor in Acute Myeloid Leukemia

Although there are many clinical and molecular biomarkers in AML, the novel and reliable biomarkers are still required to predict the overall survival at the time of disease diagnosis.

Neutropenic Enterocolitis Complicating Induction Chemotherapy in an Acute Myeloid Leukemia Patient

This study reports on a patient diagnosed with neutropenic enterocolitis within one week of receiving induction chemotherapy for acute myeloid leukemia. 

Primum Non Nocere: Allo-HSCT for AML in CR1

This study demonstrates the potential applicability of a knowledge bank to inform decision making as to whether patients ages 18 to 59 years with AML should undergo allogeneic HSCT...

Post-Transplant Maintenance Therapy for Patients with Acute Myeloid Leukemia: Current Approaches and the Need for More Trials

The current study highlights the current evidence behind the use of post-transplant maintenance therapy, the optimal patient and disease selection...

CD9, A Potential Leukemia Stem Cell Marker, Regulates Drug Resistance and Leukemia Development in Acute Myeloid Leukemia

This study aims to identify LSC-specific surface markers and uncover the underlying mechanism of AML LSCs.

MicroRNAs Associated With a Good Prognosis of Acute Myeloid Leukemia and Their Effect on Macrophage Polarization

The present paper is focusing on miRNAs which, according to current knowledge, favorably impact on AML outcomes, being regarded as tumor suppressors, and reviews...

Frontiers in Immunology
Loss of H3K27 Methylation Identifies Poor Outcomes in Adult-Onset Acute Leukemia

This study identifies potential prognostic implications of epigenetic modification of histone proteins, with a focus on H3K4 and H3K27 methylation marks in relation to mutations...

Intermediate Dose Cytarabine Improves Survival and Relapse-Free Rate Compared With Standard-Dose Cytarabine as Post-Remission Treatment for Acute Myeloid Leukemia

This study aims to investigate the toxic effects of single-intermediate dose cytarabine in patients with AML after achieving CR, compared with standard-dose cytarabine.

Occupational Pesticide Exposure Increases Risk of Acute Myeloid Leukemia

These findings broaden the spectrum of pesticide toxicity to myeloid malignancies.

Scientific Reports
Adrenomedullin-CALCRL Axis Controls Relapse-Initiating Drug Tolerant Acute Myeloid Leukemia Cells

This study's data highlights a critical role of ADM-CALCRL in post-chemotherapy persistence of these cells, and disclose a promising therapeutic target to prevent relapse in AML.

Unraveling the Role of Innate Lymphoid Cells in Acute Myeloid Leukemia

While advances have been made to understand these NK cell defects in the setting of AML, the role of other closely related and recently discovered members of the ILC family is much less clear.

Different Methylation Signatures at Diagnosis in Patients With High-Risk Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia Predict Azacitidine Response and Longer Survival

Epigenetic therapy, using hypomethylating agents, is known to be effective in the treatment of high-risk MDS and AML patients who are not suitable for intensive chemotherapy...

Deciphering Molecular Mechanisms Underlying Chemoresistance in Relapsed AML Patients: Towards Precision Medicine Overcoming Drug Resistance

This study explores the potential implementation of the characterization of chemoresistance mechanisms in individual AML patients towards efficacious personalized medicine.

Acute Myeloid Leukemia in Children: Emerging Paradigms in Genetics and New Approaches to Therapy

This study reviews key cytogenetic and molecular features of pediatric AML and how new therapies are being used to improve outcomes.

Near-Infrared Oxidative Phosphorylation Inhibitor Integrates Acute Myeloid Leukemia–Targeted Imaging and Therapy

The biggest challenge for AML therapy is the lack of methods to target and kill the heterogeneous leukemia cells, which lead to disease relapse.

Time-Dependent Treatment Effects of Metronomic Chemotherapy in Unfit AML Patients

This study examines the presence of the time-dependent effect of metronomic chemotherapy for the treatment of older patients with AML who were unfit for standard chemotherapy...

The Metabolic Reprogramming in Acute Myeloid Leukemia Patients Depends on Their Genotype and is a Prognostic Marker

Leukemic cells display some alterations in metabolic pathways, which play a role in leukemogenesis and in patients’ prognosis.

Blood Advances
Outcomes of Pediatric Acute Myeloid Leukemia Patients With FLT3-ITD Mutations in the Pre-FLT3 Inhibitor Era

This study aims to analyze the outcomes of pediatric AML patients with FLT3-ITD mutations in the pre-FLT3 inhibitor era.

Enriching for Human Acute Myeloid Leukemia Stem Cells Using Reactive Oxygen Species-Based Cell Sorting

Isolation of leukemia stem cells presents a challenge due to the heterogeneity of the immunophenotypic markers commonly used to identify blood stem cells.

Clinical Features and Outcomes of Hypocellular Acute Myeloid Leukemia in Adults

Study investigators perform a retrospective analysis of the clinical features and survival outcomes of hypocellular AML in a Korean population.

Differentiation Therapy of Myeloid Leukemia

AML is characterized by arrested differentiation, and agents that overcome this block are therapeutically useful, as shown by the efficacy of all-trans retinoic acid in...

A Modular and Controllable T Cell Therapy Platform for Acute Myeloid Leukemia

Study investigators develop a modular and controllable MHC-unrestricted adoptive T cell therapy platform tailored to AML.

SIRPαFc Treatment Targets Human Acute Myeloid Leukemia Stem Cells

Hematologic and solid tumors can upregulate expression of CD47, a self-marker that binds to SIRPα, an immunoglobulin superfamily receptor expressed on...

Acute Macular Neuroretinopathy in a Patient With Acute Myeloid Leukemia and Deceased by COVID-19

This study aims to report a case of acute macular neuroretinopathy and underlying disease of acute myeloid leukemia.

Azelaic Acid Exerts Antileukemia Effects against Acute Myeloid Leukemia by Regulating the Prdxs/ROS Signaling Pathway

The findings indicate that AZA may be a potential agent against AML by regulating the Prdxs/ROS signaling pathway.

LT-171-861, a Novel FLT3 Inhibitor, Shows Excellent Preclinical Efficacy for the Treatment of FLT3 Mutant Acute Myeloid Leukemia

Given that aberrant activation of FLT3 acts as a critical survival signal for cancer cells in 20‒30% patients with AML, inhibition of FLT3 may be a potential therapeutic strategy.

Maintenance Therapy in Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Relapse remains the main cause of treatment failure in acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation.

Measurable Residual Disease Monitoring Provides Insufficient Lead-Time to Prevent Morphological Relapse in the Majority of Patients with Core-Binding Factor Acute Myeloid Leukemia

Core-binding factor acute myeloid leukemia is characterized by t(8;21) or inv(16) and the fusion proteins RUNX1-RUNX1T1 and CBFB-MYH11.

Circulating Monocytic Myeloid-Derived Suppressor Cells Are Elevated and Associated with Poor Prognosis in Acute Myeloid Leukemia

Little is known about the roles of M-MDSCs in acute myeloid leukemia as opposed to their multiple roles in solid tumors.

FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies

The FLT3 receptor is overexpressed on the majority of acute myeloid leukemia blasts.

Frontiers in Oncology
Impact of Gemtuzumab Ozogamicin on MRD and Relapse Risk in Patients With NPM1-Mutated AML

Measurable residual disease monitoring is of prognostic relevance in NPM1mut acute myeloid leukemia patients.

Long Non-Coding RNA ZNF667-AS1 Knockdown Curbs Liver Metastasis in Acute Myeloid Leukemia by Regulating the microRNA-206/AKAP13 Axis

This study's goal is to probe the functional mechanism of ZNF667-AS1 in AML by mediating microRNA-206 (miR-206)/A-kinase anchoring protein 13 (AKAP13) axis.

Zeb1 modulates hematopoietic stem cell fates required for suppressing acute myeloid leukemia

ZEB1 expression was downregulated in AML patients, and Zeb1 KO in the malignant counterparts of HSCs—leukemic stem cells— accelerated MLL-AF9– and Meis1a/Hoxa9-d

Journal of Clinical Investigation
Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication

Both CBF-AML entities are characterized by chromosomal rearrangements involving the CBF transcriptional complex, leading to abnormal fusion proteins that block myeloid differentiation.

Blood Advances
IGFBP7 activates retinoid acid–induced responses in acute myeloid leukemia stem and progenitor cells

Study results suggest a potential clinical utility of IGFBP7 and ATRA combination treatment to eliminate primary AML cells and reduce relapse in AML patients.

Blood Advances
Chimeric Antigen Receptor-Modified Immune Effector Cell Therapy for Acute Myeloid Leukemia

This study discusses the current status of CAR-modified IEC therapies for AML, with considerations regarding suitable, relatively leukemia-restricted target antigens, expected toxicities...

Acute Myeloid Leukemia Stem Cells: The Challenges of Phenotypic Heterogeneity

The following study reviews the current knowledge on AML LSC identification and targeting via surface antigens with a focus on heterogeneity among different AML subgroups and genetic backgrounds.

Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics

Insight into Leukemia stem cells and assessment of cell surface markers have enabled characterization of LSCs from hematopoietic stem and progenitor cells.

Frontiers in Oncology
Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy

AML is the most common form of acute leukemia in adults and second most common form of acute leukemia in children. Despite this, very little improvement in survival rates...

Does patient fitness play a role in determining first-line treatment of acute myeloid leukemia?

This study presents cases of three patients with AML with varying cytogenetic and molecular risks to demonstrate the important but changing role of patient fitness in the current...

Management of toxicities associated with targeted therapies for Acute Myeloid Leukemia: When to Push Through and When to Stop

The goal of this review is to help clinicians determine the risk:benefit ratio in decision making for individual patients with AML.

Dasatinib response in acute myeloid leukemia is correlated with FLT3/ITD, PTPN11 mutations and a unique gene expression signature

This study aimed to predict in vitro response to targeted therapies, based on molecular markers, with subsequent validation in leukemic stem cells.

Natural killer cell-based immunotherapy for acute myeloid leukemia

This review summarized different forms of NK cell-based immunotherapy for AML based on preclinical investigations and clinical trials.

Deciphering the Therapeutic Resistance in Acute Myeloid Leukemia

This study reviewed the latest insights in AML biology concerning refractoriness to therapies with a specific focus on cytarabine and daunorubicin which still represent milestones agents for...

International Journal of Molecular Sciences
TP-0903 is active in models of drug-resistant acute myeloid leukemia

Effective treatment for AML is challenging due to the presence of clonal heterogeneity and the evolution of polyclonal drug resistance.

Bone marrow stromal cells induce an ALDH+ stem cell-like phenotype and enhance therapy resistance in AML through a TGF-β-p38-ALDH2 pathway

The bone marrow microenvironment in acute myeloid leukemia consists of various cell types that support the growth of AML cells and protect them from chemotherapy. 

Application of machine learning in the management of acute myeloid leukemia: current practice and future prospects

This comprehensive review highlights and discusses recent advances in ML techniques in the management of AML as a model disease of hematologic neoplasms...

Blood Advances
Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia

This review discussed FLT3 as a target and highlight current understanding of FLT3 inhibitor resistance.

Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments

Treatment of FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD)-positive acute myeloid leukemia remains a challenge despite the development of novel FLT3-directed...

Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death

This study investigated the combination effects of radotinib and Ara-C on AML.

BMC Cancer
New directions for emerging therapies in acute myeloid leukemia: the next chapter

Conventional therapy for acute myeloid leukemia is composed of remission induction with cytarabine- and anthracycline-containing regimens, followed by consolidation therapy, including...

Pharmacologic Therapies to Prevent Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation

This study summarizes the current knowledge about the preemptive and prophylactic use of pharmacologic agents after allo-HSCT to prevent relapse of AML.

Frontiers in Oncology
Advances in Acute Myeloid Leukemia: Recently Approved Therapies and Drugs in Development

Recently, numerous advancements have been made within the realm of AML therapy, including genetically targeted therapies against FLT3, IDH1/2 and tumor protein p53, antibody-drug conjugate

The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs

This study characterized a new multiple kinase inhibitor, ARQ531, and evaluate its mechanism of action in preclinical models of acute myeloid leukemia.

The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia

The SITC convened a panel of experts to develop a clinical practice guideline composed of consensus recommendations on immunotherapy for the treatment of ALL and AML.

A compound combination screening approach with potential to identify new treatment options for paediatric acute myeloid leukaemia

Recently age-specific differences in AML have been identified, highlighting the need for tailored treatments for paediatric patients.

Scientific Reports
Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions

Notably, venetoclax-based combinations have improved outcomes, including both remission rates and overall survival, of older patients with AML deemed “unfit” for intensive...

Frontiers in Oncology
Targeting Bcl-2 Proteins in Acute Myeloid Leukemia

Overexpression of BCL-2 proteins in acute myeloid leukemia can circumvent resistance to apoptosis and chemotherapy.

Frontiers in Oncology
Immune prognostic risk score model in acute myeloid leukemia with normal karyotype

NK-AML is a group of diseases with high heterogeneity and immunological processes are significantly associated with its initiation and development.

Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia of the Elderly: Review of Literature and New Perspectives

The increasing knowledge of AML in the elderly is currently being associated with a multidimensional approach to identify eligibility and design tailored transplant platforms.

Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy

Like normal hematopoietic stem cells, leukemic stem cells depend on their bone marrow microenvironment for survival, but the underlying mechanisms remain largely unknown.


source list reference